CEO Richard Clark

Amylin Pharmaceuticals Inc. (AMLN) (AMLN), the diabetes drugmaker that has put itself up for sale, received offers from Sanofi (SAN) and Merck & Co. in an initial round of bidding, said three people familiar with the process. The companies made bids of at least $25 a share, said the people, who declined to be identified as the deliberations are private. That would value Amylin at more than $4 billion...  

Merck & Co. CEO Kenneth Frazier tells company shareholders that this year and next will be difficult. Speaking at the companys annual meeting, Frazier noted the drugmakers top-selling product, asthma and allergy drug Singulair, gets U.S. generic competition soon. That will sharply reduce revenue from Singulair, which brought in $5.5 billion last year. He also cited an uncertain global economy. But...  

Analysts think that New Jersey-based Merck & Co. Inc. (NYSE: MRK), a company with a Durham-based vaccine manufacturing facility, could be a potential buyer for San Diego-based Amylin Pharmaceuticals, Inc. That’s according to a report from Reuters that says Amylin started reaching out to potential buyers last week. Amylin (Nasdaq: AMLN) already rejected a $3.5 billion takeover bid from Bristol-Myers Squibb Company (NYSE: BMY) in March. Other...  

BOSTON -- A US district court judge in Boston on Thursday ordered Merck & Co. to pay a $321.6-million criminal fine for its violation of a federal drug law in connection with its marketing of the former painkiller Vioxx. In December, Merck pleaded guilty to violating the Federal Food, Drug...  

ALBANY, N.Y. — New York Attorney General Eric Schneiderman says New York will get $61 million from this week's national settlement with drug maker Merck & Co. to resolve an investigation into the marketing of the painkiller Vioxx. A federal court has accepted Merck's guilty plea to one misdemeanor...  

Merck & Co. Inc. entered into an agreement Monday with Endocyte Inc. to develop and commercialize Endocyte’s experimental cancer therapy in a deal potentially worth $1 billion. Under the terms of the agreement, Merck (NYSE:MRK) will make a $120 million upfront payment to Endocycte of West Lafayette, Ind. Endocyte (NASDAQ:ECYT) could earn up to $880 million in milestone payments based on regulatory approvals and sales performance. In return...  

Merck & Co. Inc. is teaming up with “American Idol” judge and Grammy Award-winning music producer Randy Jackson for an awareness campaign aimed at getting people with type 2 diabetes to commit to a healthier lifestyle. Jackson was diagnosed with type 2 diabetes in 2003. He will be touring the country with Merck (NYSE:MRK) representatives for the pharmaceutical company’s “Take Diabetes to Heart” campaign. Jackson will share his personal...  

Amylin Pharmaceuticals Inc. (AMLN), the diabetes drugmaker that has put itself up for sale, received offers from Sanofi (SAN) and Merck & Co. in an initial round of bidding, said three people familiar with the process. The companies made bids of ...  

A follow-up study on an AIDS vaccine trial that had to be stopped early has confirmed the worst fears of researchers: The vaccine made it more likely, not less, that some men would become infected with H.I.V. Men who were not circumcised and who had previously caught common colds caused by the same virus used to make the vaccine were two to four times as likely as other men to become infected if they...  

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--At their meeting today, the Board of Directors of Merck & Co., Inc. declared a quarterly dividend of $0.42 per share on the company’s common stock for the third quarter of 2012. Payment will be made on July 9, 2012 to stockholders of record at the close of business on June 15, 2012. About Merck Today's Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside...  

Amylin Pharmaceuticals Inc., the diabetes drugmaker that’s up for sale, has received first-round bids from Sanofi and Merck & Co., said three people familiar with the process. The companies made offers of at least $25 a share, said the people ...  

BRIDGEWATER, N.J. (AP) - Merck & Co. CEO Kenneth Frazier tells company shareholders that this year and next will be difficult. Speaking at the company's annual meeting, Frazier noted the drugmaker's top-selling product, asthma and allergy drug Singulair ...  

Merck & Co. (MRK) isnt liable in Australia for heart risks associated with the Vioxx painkiller, the countrys top court ruled, upholding an appeal of the first trial decision outside the U.S. Graeme Robert Peterson was awarded A$287,912 ($290,000) in a 2010 ruling that found Vioxx contributed to his heart attack in 2003, and a Federal Court appeal panel in Melbourne reversed that decision in October...  

AUGUSTA - Attorney General William J. Schneider announced today that Maine has received payment of more than $1.1 million in a nationwide settlement with pharmaceutical manufacturer Merck Sharp & Dohme Corp. (Merck) involving allegations of off-label marketing and failure to disclose potential adverse health effects of the painkiller Vioxx.The settlement agreement, reached with the United States and 43 states and the District of Columbia in...  

After almost 13 years of study and intense debate, researchers have shed light on exactly how a once-popular class of anti-inflammatory drugs leads to cardiovascular risk for people taking it. It has been almost eight years since Vioxx was withdrawn by Merck from the market, provoking an intense controversy about the role inhibitors of the enzyme COX-2 play in causing heart attacks and strokes. Since...  

Triangle Business Journal by Jason deBruyn, Staff Writer Pharmaceutical giant Merck & Co. Inc. announced a $15 million investment in two projects at its Wilson facility on Wednesday.In one project, Merck (NYSE: MRK) will renovate manufacturing space and in another project it will build a new cold storage facility for vaccine packaging to support the companys growing vaccines...  

Mention Gardasil, the Merck vaccine against four strains of the cancer-causing human papilloma virus, and youre likely to get a comment like this one, which reader Heather Meyers left on my story, The Gardasil Problem, which appeared recently in Forbes Magazine.  

KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--Trevena, Inc., the leader in the discovery and development of G-protein coupled receptor (GPCR) biased ligands, today announced the initiation of a research collaboration with Merck, through a subsidiary. The collaboration will focus on screening for biased ligands against an undisclosed receptor using Trevenas proprietary assays and know-how. Financial details...  

Triangle Business Journal by Lauren K. Ohnesorge, Staff Writer An international vaccines groups recent deal with GlaxoSmithKline (NYSE: GSK) and Merck (NYSE: MRK) will result in lower prices for rotavirus shots in third world countries.Vaccines group GAVI is bulk buying GSKs Rotarix and Mercks Rotateq, vaccines that combat the main cause of diarrhea, which is the second largest...  

Merck & Co, known as MSD outside the United States and Canada, has won patent infringement suits against Mylan Pharmaceuticals Inc., in respect of Zetia and Vytorin. The US District Court for the District of New Jersey has ruled in Merck's favour in two jointly related patent infringement suits. "The court appropriately ruled that the patent for Zetia and Vytorin in the US is valid and enforceable...  

There is a ridiculous article here which claims, in effect, that the executives of Merck & Co should have been hanged, drawn and quartered for releasing the anti-arthritis drug Vioxx. It is all rather water under the bridge now so I won’t go into great detail but but I believe Vioxx was unfairly impugned and should [...]  

A unit of Merck & Co. (MRK), the second- largest U.S. drugmaker, pleaded guilty to a criminal misdemeanor charge as part of a $950 million settlement of a U.S. government probe of its illegal marketing of the painkiller Vioxx. An official of Merck Sharp & Dohme said today that the company agreed to plead guilty to one count of misbranding Vioxx. U.S. District Judge Patti Saris in Boston accepted the plea as part of the drugmaker’s...  

Merck & Co. (MRK) Q1 2012 Earnings Call April 27, 2012 8:00 am ET Executives Alex Kelly - Kenneth C. Frazier - Chairman, Chief Executive Officer, President and President of Global Human Health Adam H. Schechter - Executive Vice President and President of Global Human Health Peter N. Kellogg - Chief Financial Officer and Executive Vice President Analysts Jami Rubin - Goldman Sachs Group Inc., Research Division Christopher Schott - JP...  

U.S. drug regulators are changing the label for Merck & Co Inc's recently approved Victrelis treatment for hepatitis C to show it should not be taken with some widely used HIV medicines. "Co-administration (of the two drugs) ... is not recommended at this time because of the possibility of reducing the effectiveness of the medicines, permitting the amount of HCV (hepatitis C virus) or HIV ... in the...  

(AP) BRIDGEWATER, N.J. - Merck & Co. (MRK) CEO Kenneth Frazier tells company shareholders that this year and next will be difficult. Speaking at the company's annual meeting, Frazier noted the drugmaker's top-selling product, asthma and allergy ...  

Last week, Bloomberg reminded us of the legal baggage that pharmaceutical giant Merck is carrying. The company had announced yet another settlement of legal actions pertaining to its ill-starred but very profitable sales of now withdrawn Vioxx (rofecoxib) in 2011 (see post here). Now the settlement, including a guilty plea was accepted by a judge. A unit of Merck & Co. (MRK), the second- largest U.S. drugmaker, pleaded guilty to a criminal...  

WHITEHOUSE STATION, N.J. -- Drugmaker Merck & Co. has won two patent infringement lawsuits against a generic drugmaker seeking to make copycat versions of its lucrative cholesterol pills, Zetia and Vytorin. Merck says U.S. District Judge Jos Linares in Newark, N.J., ruled Friday against Mylan Pharmaceuticals Inc. > > Bull or Bear? Vote in Our Poll ... Click to view a price quote on MRK. Click...  

BARCELONA, April 19, 2012 /PRNewswire/ - Today Merck announced results demonstrating no difference in the rates of viral clearance between two anemia management strategies for patients with chronic hepatitis C virus (HVC) genotype 1 infection treated with VICTRELIS (boceprevir) in combination with peginterferon...  

Merck & Co. Inc. reported a 67 percent profit increase Friday for the first quarter of this year compared with the same period in 2011, but the number was helped by cost-cutting and absence of a big charge from a year ago. The global drugmaker, which is based in Whitehouse Station, N.J., and has big operations in the Philadelphia suburbs, got the profit increase in part by spending less.  

BARCELONA, Spain--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced final results from a Phase III, open-label study designed to compare the impact of two anemia management strategies on sustained virologic response (SVR)1 in patients with chronic hepatitis C virus (HCV) genotype 1 infection treated with VICTRELIS (boceprevir) in combination with PEGINTRON...  

Drugmaker Merck & Co. said Friday that its first-quarter profit jumped 67 percent despite lower-than-expected sales, due to lower spending on production, marketing and research as well as an arbitration charge a year ago. The maker of Singulair for asthma and allergies said net income was $1.74 billion, or 56 cents per share, up from $1.04 billion, or 34 cents per share, a year earlier. Excluding one-time items such as integration of acquired...  

WHITEHOUSE STATION N.J. & WEST LAFAYETTE, Ind., Apr 16, 2012 (BUSINESS WIRE) -- Merck, known as MSD outside the United States and Canada, MRK -1.27% and Endocyte Inc. ECYT 104.47% , today announced that they have entered into an agreement to develop and commercialize Endocyte's novel investigational therapeutic candidate vintafolide (EC145). Vintafolide is currently being evaluated in a Phase III...  

By Christopher Grosvenor:In this article, we take a look at Johnson & Johnson (JNJ), Pfizer (PFE) and Merck (MRK). All three enterprises are rated "Buy"; however, share prices could decline in the coming months as economic headwinds impact valuations.The pharmaceutical industry is concentrated with strong pricing power. It is a mature industry with little growth, industry consolidation and high barriers to entry. Populations of developed...  

Warning labels for Merck & Co's drugs for baldness and enlarged prostate will add notices of sexual side effects that continued after use of the medicines was stopped, U.S. health regulators said.Labels will be revised for Proscar, which treats symptoms of enlarged prostate, and hair-loss treatment Propecia, the Food and Drug Administration said. The active ingredient in both drugs is finasteride...  

BLUE BELL, Pa., Mar. 27, 2012  /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO) announced today Dr. Adel Mahmoud, a global infectious disease and vaccines expert, has been appointed to Inovio's Board of Directors. During his long tenure at Merck & Co., Dr....  

BAGSVAERD, DENMARK--(Marketwire - April 06, 2012) - Novo Nordisk today announced that the USFood and Drug Administration (FDA) hasapproved to update the product label for Victoza® (liraglutide [rDNA]injection) to include data showing superior blood sugar control and weightreduction when compared to Januvia® (sitagliptin).Company announcement ...  

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Codexis, Inc. (Nasdaq:CDXS) announced today that collaborative research conducted by Merck and Codexis scientists to develop a highly efficient, enzyme-based production method for a key intermediate in the production of boceprevir has been recently published in the Journal of the American Chemical Society (JACS). Boceprevir is the active ingredient in Merck's...  

A new once-daily AIDS drug from GlaxoSmithKline and its partner Shionogi proved just as good as Merck & Co's twice-daily rival Isentress in a late-stage clinical trial, boosting hopes for the product. Both GSK's new drug dolutegravir and Isentress are so-called integrase inhibitors, a novel class of drugs for fighting HIV/AIDS that block the virus causing the disease from entering cells. Dolutegravir...  

Neal Fowler, 50, the chief executive officer of a tiny biotech called Liquidia, was assuming a position common to road-warrior entrepreneurs: leaning his elbows on the seat-back tray in an airplane so he could gaze at the screen of his laptop. Thats when he felt the lump in his neck. Fowler, a pharmacist, figured his lymph node was swollen by a recent cold, but the oncologist seated next to him...  

CHICAGO--(BUSINESS WIRE)--Researchers today presented and published results from the TRA-2P (Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events) TIMI 50 study of vorapaxar, Merck's investigational anti-thrombotic medicine, in patients with a prior history of cardiovascular events or disease. In the study, the addition of vorapaxar to standard of care (e.g. aspirin...  

We saw some investments this week in New England regenerative medicine, diagnostics, and medical devices companies. —Cambridge, MA-based Flagship Ventures formed a new partnership with Merck Research Ventures Fund to find and finance companies developing drugs for unmet medical needs. The $250 million Merck fund was established last fall and has so far made four [...]  

New York Attorney General Eric Schneiderman says New York will get $61 million from last week’s national settlement with drug maker Merck & Co. to resolve an investigation into the marketing of the painkiller Vioxx. A federal court has accepted …  

By The Associated Press PROFIT JUMP: Merck & Co.'s first-quarter profit rose 67 percent to $1.74 billion, due to lower spending and a $500 million payment a year ago to end arbitration over rights...  

After reading the Examiner's coverage on the devastating side effects of Merck & Co.’s hair-growth drug Propecia, more men are now coming forward to say they are also unsuspecting victims. One victim who says the drug ruined his life is 30 ...  

The most common type is diabetic peripheral neuropathy, which causes pain or loss of feeling in the ... in patients with advanced renal cell carcinoma whose disease had progressed on or after Sutent (sunitinib malate) therapy did not meet the primary ...  

Merck & Co. (MRK) isn’t liable in Australia for heart risks associated with the Vioxx painkiller, the country’s top court ruled, upholding an appeal of the first trial decision outside the U.S. Merck withdrew Vioxx in 2004 after a study ...  

Drugmaker Merck & Co. said Friday that its first-quarter profit jumped 67 percent despite lower-than-expected sales, due to lower spending on production, marketing and research as well as an arbitration charge a year ago.  

This is Dr. Paul Sax, from Brigham and Women's Hospital and Harvard ... Merck & Co., Inc.; Tibotec, Inc. Received research grant from: Bristol-Myers Squibb Company; Gilead Sciences, Inc.; Merck & Co., Inc.; GlaxoSmithKline; Tibotec, Inc.  

Drugmaker Merck & Co., discussing its first-quarter results, said it will apply for approval by the end of 2013 for five new products, including a new type of drug to fight bone-thinning osteoporosis, odanacatib. Merck pioneered osteoporosis drugs ...  

Merck & Co pleaded guilty in recent months to having illegally promoted Vioxx for treatment of rheumatoid arthritis before it was approved for that use in 2002. The pill, approved in 1999 as a painkiller, was withdrawn from the market in 2004 after it was ...  

Vioxx off-label marketing activities are going to cost Merck & Co. a whopping $321 million in criminal fines. The U.S. Food & Drug Administration (FDA) approved Vioxx (rofecoxib), a painkiller, for three indications in May 1999. Merck has pleaded guilty … Continue reading →  

Drugmaker Merck & Co., discussing its first-quarter results, said it will apply for approval by the end of 2013 for five new products, including a new type of drug to fight bone-thinning osteoporosis, odanacatib. Merck pioneered osteoporosis ...  

Today they are providing members comprehensive research on the Drug Manufacturers - Major industry and are offering free analytical research on Merck & Co. Inc. (NYSE: MRK - News) and Eli Lilly & Co. (NYSE: LLY - News). Register with us today at ...  

(Reuters) - Merck & Co reported quarterly earnings slightly above Wall Street forecasts, helped by cost controls, but revenue trailed expectations on generic competition and reduced revenue from alliances with other drugmakers. The No. 2 U.S. drugmaker on ...  

A unit of Merck & Co., the second-largest U.S. drugmaker, pleaded guilty to a criminal misdemeanor charge as part of a $950 million settlement of a U.S. government probe of its illegal marketing of the painkiller Vioxx. An official of Merck Sharp & Dohme said Thursday that the company agreed to plead guilty to one count of misbranding Vioxx. U.S. District Judge Patti Saris in Boston accepted the ...  

Legal News LineMerck: Challenge of Ky. AG's contract with private lawyers should continueLegal News Line(Legal Newsline) - Merck & Co.'s challenge of a contingency fee contract given by Kentucky Attorney General Jack Conway to private attorneys will not interfere with any state proceedings and should not be dismissed, the company is arguing.  

(Reuters) - A Boston federal judge on Thursday sentenced Merck & Co to pay a $321 million criminal fine for improperly marketing its Vioxx painkiller a decade ago. The U.S. drugmaker pleaded guilty in recent months to having illegally promoted Vioxx for treatment of rheumatoid arthritis before it was approved for that use in 2002. The pill, approved in 1999 as a painkiller, was withdrawn from ...  

(Reuters) - A U.S. court on Friday ruled that the patent on Merck & Co's (MRK.N) cholesterol fighter Zetia and a related drug Vytorin was valid and issued an injunction blocking approval of a generic version by Mylan Inc (MYL.O) until the patent ...  

The company’s Pharmaceutical segment provides human health pharmaceutical products, such as therapeutic and preventive agents for the treatment of human disorders in the areas of bone, respiratory, immunology, dermatology, cardiovascular diseases ...  

A U.S. district court judge in Boston ordered Merck & Co. (MRK) to pay a $321.6 million criminal fine for its violation of a federal drug law in connection with its marketing of the former painkiller Vioxx. In December, Merck pleaded guilty to ...  

New York Attorney General Eric Schneiderman said New York will get $61 million from this week's national settlement with drug maker Merck & Co. to resolve an investigation into the marketing of the painkiller Vioxx. A federal court has accepted Merck's ...  

Law360, Los Angeles (May 02, 2012, 6:38 PM ET) -- Former Merck & Co. Inc. associate general counsel and vice president John L. Sander has joined Jackson Lewis LLP as a partner in its New York office, the firm announced Wednesday, welcoming an international ...  

Pharmaceutical giant Merck & Co. Inc. Merck & Co. Inc. Latest from The Business Journals Hewlett Packard’s Philadelphia connection Codexis gets FDA approval of pharma ingredient IMS Health to buy clinical trials software company DecisionView ...  

Exxon Mobil, GM, Home Federal, Merck: US Equity PreviewBloombergHome Federal Bancorp Inc. (HOME) : The holding company for Home Federal Bank of Nampa, Idaho reported first-quarter earnings of 5 cents a share, beating the average of two analyst estimates by 2 cents. Merck & Co. (MRK) : The second-largest US ...and more »  

Drugmaker Merck & Co says its first quarter profit jumped 67 per cent despite lower-than-expected sales, due to lower spending on production, marketing and research as well as an arbitration charge a year ago. The maker of Singulair for asthma and ...  

Tallahassee, FL 4/27/12 (StreetBeat) -- Drugmaker Merck & Co. (NYSE: MRK) said Friday that its first-quarter profit jumped 67 percent despite lower-than-expected sales, due to lower spending on production, marketing and research as well as an arbitration ...  

PROFIT JUMP: Merck & Co.'s first-quarter profit rose 67 percent to $1.74 billion, due to lower spending and a $500 million payment a year ago to end arbitration over rights to two drugs. MIXED SALES: Revenue grew 1 percent to $11.7 billion. Surging sales ...  

BloombergMerck 1Q Net Rises 67% On Lower Costs; Sales Growth SlowsWall Street JournalBy Peter Loftus Of DOW JONES NEWSWIRES Merck & Co. (MRK) reported a 67% increase in first-quarter profit on lower costs, while a deceleration in sales growth for blockbuster diabetes drug Januvia and a decline in alliance revenue contributed to modest ...Merck profit beats forecast, revenue lagsReutersMerck posts big Q1 profit jump on lower...  

Merck & Co. reported a 67% increase in first-quarter profit on lower costs, while a deceleration in sales growth for blockbuster diabetes drug Januvia and a decline in alliance revenue contributed to modest overall revenue growth. The Whitehouse ...  

Merck & Co. ( MRK) reported first quarter 2012 earnings per share (excluding special items) of 99 cents, a penny above the Zacks Consensus Estimate and 7.6% above the year-ago earnings. Revenues for the quarter increased 1.3% to $11,731 million ...  

Merck & Co. (MRK)’s patent for the cholesterol drugs Zetia and Vytorin is valid and enforceable, a federal judge ruled today in a case against Mylan Inc. (MYL), which sought to sell generic versions of the drugs before the patent expires.  

WASHINGTON (Reuters) - U.S. drug regulators are changing the label for Merck & Co Inc's recently approved Victrelis treatment for hepatitis C to show it should not be taken with some widely used HIV medicines. "Co-administration (of the two drugs)  

According to Merck & Co., the company faces more than 950 NuvaRing side effects lawsuits alleging NuvaRing caused serious injuries, including blood clots, deep vein thrombosis, pulmonary embolism, heart attacks, strokes and wrongful death. Melville ...  

A federal judge has upheld the validity of a U.S. patent covering Merck & Co.'s (MRK) Vytorin cholesterol-lowering drug, which could stave off competing generic copies for several years. In an opinion released Friday, U.S. District Judge Jose ...  

Law360, New York (April 19, 2012, 5:15 PM ET) -- People for the Ethical Treatment of Animals have dropped a securities suit meant to ensure Merck & Co. Inc. shareholders would be informed of concerns over the drugmaker's care of animals after a Virginia ...  

Merck & Co.'s (MRK) leader received compensation valued at $13.3 million ... at the beginning of 2011 and chairman of the board in December. He was previously head of Merck's human health business. In a proxy statement filed Thursday with ...  

NEW YORK - Endocyte Inc. said Monday that Merck & Co. will help develop and market its experimental cancer drug vintafolide, and Endocyte could get more than $1 billion if the drug is successfully developed as a treatment for multiple types of cancer.  

WHITEHOUSE STATION, N.J.—Drugmaker Merck & Co. has won two patent infringement lawsuits against a generic drugmaker seeking to make copycat versions of its lucrative cholesterol pills, Zetia and Vytorin. Merck says U.S. District Judge José ...  

TRENTON, N.J. (AP) -- Merck & Co., a Dow component and the world's third-biggest drugmaker by revenue, will focus on approvals of a couple of new drugs, sales of key products and drugs in development when it reports its first-quarter results ...  

Endocyte Inc said Merck & Co Inc had acquired the development and marketing rights of its experimental cancer drug, the latest in the string of licensing deals by the No. 2 U.S. drugmaker to beef up its cancer drug pipeline. Shares of Endocyte, which had a ...  

Tomahawk, WI 4/16/2012 (StreetBeat) -- Endocyte (ECYT) was up more than 100 percent on heavy volume. Merck & Co. (MRK) has agreed to pay $120 million upfront to Endocyte Inc., with additional payouts of up to $880 million, to develop and market the ...  

Proactive Investors USA & CanadaInovio appoints vaccines, bioterror expert to its boardGovernment Security NewsDuring a long tenure at Merck & Co., Mahmoud was responsible for the development and commercialization of several new important vaccines, including Gardasil, Zostavax, Proquad and Rotateq, said Inovio. He retired from Merck in 2005.Inovio appoints Adel Mahmoud to company boardProactive Investors USA & CanadaInovio Appoints Retired...  

Merck & Co. (MRK), the second-largest U.S. drugmaker, reported first-quarter profit that beat analyst estimates on higher sales of its diabetes treatments. Sales rose 1.3 percent to $11.7 billion. Merck is preparing for falling sales of its ...  

USA TODAYMERCK & CO., INC. : WSJ UPDATE : Merck Anticlotting Drug Shows Benefit And ...4-tradersBy Ron Winslow and Peter Loftus Merck & Co.'s (MRK) experimental anticlotting drug vorapaxar proved effective in preventing heart attacks and other events for patients with heart disease in a major study, but the price was a sharp increase in the risk ...Merck ponders next step for troubled heart drugBusinessWeekMerck Anticlotting Drug Shows Benefit...  

ZOSTAVAX is not indicated for the treatment of shingles or postherpetic neuralgia (PHN ... Deferral should be considered in acute illness (for example, in the presence of fever) or in patients with active untreated tuberculosis. Vaccination with ZOSTAVAX ...  

Private MDSexual side effects added to Merck drug labelsReuters* Labels changed for drugs for baldness, enlarged prostate * Proscar, Propecia effects continued after use was ended-FDA April 12 (Reuters) - Prescribing labels for Merck & Co's drugs for baldness and enlarged prostate will add reports of sexual side ...FDA adds sexual side effects warning to baldness drug PropeciaCBS NewsBaldness, prostate drugs get sexual side effects...  

REUTERS - Warning labels for Merck & Co's drugs for baldness and enlarged prostate will add notices of sexual side effects that continued after use of the medicines was stopped, U.S. health regulators said. Labels will be revised for Proscar, which treats symptoms of enlarged prostate, and hair-loss treatment Propecia, the Food and Drug Administration said. The active ingredient in both drugs is ...  

Proactive Investors USA & CanadaThreshold Pharma lands $20M milestone from Merck KGaAFierceBiotechThe most advanced of these trials is a Phase III pivotal study evaluating TH-302 in combination with doxorubicin versus doxorubicin alone in patients with soft tissue sarcoma. "The achievement of this milestone validates the encouraging results seen in ...Threshold Pharmaceuticals Earns $20 Million Milestone Payment From Merck KGaA ...MarketWatch...  

As published on February 28th, 2012 in Merck & Co., Inc. form 10-K annual report for the fiscal year 2011, approximately 950 NuvaRing lawsuits were pending as of Dec. 31st 2011. The plaintiffs seek damages for injuries allegedly sustained from their NuvaRing use, including some alleged deaths, heart attacks and strokes. NuvaRing is a popular internal birth control device, a vaginal ring placed ...  

A state court jury in New Jersey has ruled in favor of Merck & Co. (MRK) and rejected a woman's claims that the company's Fosamax drug caused jaw-related problems, marking Merck's latest victory in a string of litigation over its osteoporosis ...  

Merck & Co.: Merck & Co. provides various health care products ... JNJ also had an EPS growth rate of -1.4% during the last five years. 5. Philip Morris: Philip Morris manufactures and sells cigarettes and other tobacco products.PM recently traded at ...  

(RTTNews) - Codexis Inc. (CDXS: News ) said Tuesday its collaborative research with Merck & Co. Inc. (MRK: News ) to develop a highly efficient, enzyme-based production method for a key intermediate in the production of boceprevir has been recently ...  

Merck operates in four segments namely, pharmaceutical, animal health, consumer care and alliance segment and competes with other health care companies like Pfizer(PFE), Johnson & Johnson and Abbott Labs (ABT). Check out our complete analysis of ...  

Meanwhile, with Merck transferring exclusive marketing rights for Remicade and Simponi to Johnson & Johnson, Remicade and Simponi combined sales fell 26%. We expect Merck to focus on improving penetration rates and drive growth in Europe, Russia and Turkey.  

A new once-daily AIDS drug from GlaxoSmithKline and its partner Shionogi proved just as good as Merck & Co's twice-daily rival Isentress in a late-stage clinical trial, boosting hopes for the product. Both GSK's new drug dolutegravir and Isentress are so ...  

Codexis and Merck & Co. report the development of a highly efficient, enzyme-based production method for a key intermediate in the production of boceprevir, the active ingredient in Merck's Vitrelis, approved for HCV. The companies point out ...  

Pfizer Inc. (PFE) and Merck & Co. (MRK) are being pulled into an expanding congressional investigation into the agreement drugmakers reached with the Obama administration to support the Democrats’ overhaul of the U.S. health-care system ...  

Pro Bono Partnership Honors Merck and Jackson LewisCitybizlist (press release)These outstanding volunteers were recognized at a March 22 reception hosted by Hogan Lovells at Hogan's Manhattan office: Merck & Co.; Jackson Lewis; and attorneys Patricia A. Bowen, UnitedHealthcare Employer & Individual; Melanie L. Brown, BASF; ...  

Merck to take more time with blood thinnerHerald and NewsCHICAGO (AP) — Officials at drugmaker Merck & Co. say they will take more time to decide what to do about an experimental blood thinner that gave disappointing results in a second big study. The study was aimed at preventing repeat heart attacks and ...and more »  

Merck blood clot drug in limbo after mixed resultsBaltimore SunCHICAGO (Reuters) - Impressive efficacy but worrisome bleeding was seen for a new type of blood clot preventer tested by Merck & Co in one of the largest heart-drug studies ever conducted, raising questions whether the company will seek approval of the ...  

Endocyte Inc. (ECYT) (ECYT) shares more than doubled after entering an agreement to develop its ovarian cancer treatment with Merck & Co. Endocyte gained (ECYT) $3.82 to $7.62 at 4 p.m. New York time, the biggest jump since the shares began ...  

Merck & Co. (MRK) (MRK), the second-largest U.S. drugmaker, reported first-quarter profit that beat analyst estimates (MRK) on higher sales of diabetes treatments. Net income (MRK) rose 67 percent to $1.74 billion, or 56 cents a share ...  

TRENTON, N.J. - Drugmaker Merck & Co. said Friday that its first-quarter profit jumped 67 per cent despite lower-than-expected sales, due to lower spending on production, marketing and research as well as an arbitration charge a year ago.  

The No. 2 U.S. drugmaker on Friday reported net income attributable ... which had sold it for years under an arrangement with J&J.; Cozaar, a blood pressure drug now facing cheaper generics, also dampened results, with sales falling 21 percent ...  

Merck & Co. (MRK)’s baldness drug Propecia and enlarged prostate therapy Proscar will carry labels linking them to sexual dysfunction after the treatments are no longer used, U.S. regulators said. Propecia’s packaging will include warnings ...  

Drug maker Merck & Co. Inc. said Thursday a federal court accepted its $950 million payment to resolve an investigation into the marketing of its painkiller Vioxx.  

Endocyte Inc. said Monday that Merck & Co. will help develop and market its experimental cancer drug vintafolide, and Endocyte could get more than $1 billion if the drug is successfully developed as a treatment for multiple types of cancer.  

Merck & Co. (MRK) reported a 67% increase in first-quarter profit on lower costs, while a deceleration in sales growth for blockbuster diabetes ... and maintain 2012 revenue at or near 2011 levels, excluding effects of currency rates.  

(RTTNews.com) - Codexis Inc. (CDXS) said Tuesday its collaborative research with Merck & Co. Inc. (MRK) to develop a highly efficient, enzyme-based production method for a key intermediate in the production of boceprevir has been recently ...  

(RTTNews.com) - Merck & Co. Inc. (MRK) announced that GRAMMY Award-winning music producer and American Idol judge Randy Jackson, diagnosed with type 2 diabetes in 2003, is using his personal experience to help others with type 2 diabetes ...  

WHITEHOUSE STATION, N.J. (AP) — Merck & Company says it won two patent infringement lawsuits against Mylan Pharmaceuticals, a leading generic drug maker, which is seeking to make generic versions of Merck’s lucrative cholesterol pills ...